Baldry Mark 4/A
4/A · X4 Pharmaceuticals, Inc · Filed Jun 3, 2025
Insider Transaction Report
Form 4/AAmended
Baldry Mark
Chief Commercial Officer
Transactions
- Award
Common Stock
2025-05-16$2.48/sh+1,032$2,561→ 25,337 total
Footnotes (1)
- [F1]On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share. Such transaction was exempt under both Rule 16b-3(d) and Rule 16b-3(c) of the Securities Exchange Act of 1934, as amended.